Update on the use of biologics in lupus

Current Pharmaceutical Biotechnology

Volumn 15, Issue 6, 2014, Pages 516-520

  Relan, Manisha ^a   Vishwanath, Sahana ^a   Shen, Long ^a   Ambrus, Julian L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibodies; Biologics; Lupus; Monoclonal antibody; SLE; Systemic lupus erythematosus; Treatment

Indexed keywords

ABATACEPT; ATACICEPT; BELATACEPT; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; METHOTREXATE; MILATUZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; OMALIZUMAB; PLACEBO; RITUXIMAB; SIFALIMUMAB; TABALUMAB; ANTIBODY CONJUGATE; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84907179691     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140804162053     Document Type: Article

References (42)

1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematous clinical trials: measures of overall disease activity. Arthritis Rheum., 2004, 50, 3418-3426.
2. Prescribing information and medication guide. http://www. gene. com/download/pdf/rituxan_prescribing. pdf (Accessed February 5, 2014).
3. Rovin, B. H.; Furie, R.; Latinis, K.; Looney, R. J.; Fervenza, F. C.; Sanchez-Guerrero, J.; Maciuca, R.; Zhang, D.; Garg, J. P.; Brunetta, P.; Appel, G.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis. Rheum., 2012, 64, 1215-1226.
4. Weidenbusch M, Rommele C, Schrottle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol. Dial. Transplant., 2013, 28(1), 106-111.
5. U. S. National Institutes of Health. Clinical Trials. RING-Rituximab for Lupus Nephritis with Remission as a Goal. http://clinicaltrials. gov/show/NCT01673295 (Accessed February 5, 2014).
6. U. S. National Institutes of Health. Clinical Trials. Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis (RITUXILUP). http://www. clinicaltrials. gov/show/NCT01773616 (Accessed February 5, 2014).
7. Merrill, J. T.; Neuwelt, C. M.; Wallace, D. J.; Shanahan, J. C.; Latinis, K. M.; Oates, J. C.; Utset, T. O.; Gordon, C.; Isenberg, D. A.; Hsieh, H. J.; Zhang, D.; Brunetta, P. G. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum., 2010, 62, 222-233.
8. U. S. National Institutes of Health. Clinical Trials: A Study to Evaluate Two Doses of Ocrelizumab in Patients with Active Systemic Lupus Erythematosus (BEGIN). http://www. clinicaltrials. gov/ct2/show/NCT00539838 (Accessed February 5, 2014).
9. Herrero-Beaumont, G.; Martinez, C. M. J.; Castaneda, S. Abatacept mechanism of action: Concordance with its clinical profile. Reumatol. Clin., 2012, 8(2), 78-83.
10. Merrill, J. T.; Burgos-Vargas, R.; Westhovens, R.; Chalmers, A.; D'Cruz, D.; Wallace, D. J.; Bae, S. C.; Sigal, L.; Becker, J. C.; Kelly, S.; Raghupathi, K.; Li, T.; Peng, Y.; Kinaszczuk, M.; Nash, P. The efficacy and safety of abatacept in patients with non-lifethreatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2010, 62(10), 3077-3087.
11. Wofsy, D.; Hillson, J. L.; Diamond, B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum., 2012, 64(11), 3660-3665.
12. U. S. National Institutes of Health. Clinical Trials. Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis. http://clinicaltrials. gov/show/NCT01714817 (Accessed February 15, 2014).
13. U. S. National Institutes of Health. Clinical Trials. Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis. http://clinicaltrials. gov/show/NCT00430677 (Accessed February 15, 2014).
14. Furie R, Nicholls K, Cheng T-T, Houssiau F, Burgos-Vargas R, Chen S-L, Hillson JL, Meadows-Shropshire S, Kinaszczuk M, Merrill JT. Efficacy and safety of abatacept in lupus nephritis. Arthritis Rheum., 2014, 66(2), 379-389.
15. U. S. National Institutes of Health. Clinical Trials. Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS). http://clinicaltrials. gov/show/NCT00774852 (Accessed February 15, 2014).
16. Wofsy, D.; Hillson, J. L.; Diamond, B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum., 2013, 65(6), 1586-1591.
17. Moore, P. A.; Belvedere, O.; Orr, A.; Pieri, K.; LaFleur, D. W.; Feng, P.; Soppet, D.; Charters, M.; Gentz, R.; Parmelee, D.; Li, Y.; Galperina, O.; Giri, J.; Roschke, V.; Nardelli, B.; Carrell, J.; Sosnovtseva, S.; Greenfield, W.; Ruben, S. M.; Olsen, H. S.; Fikes, J.; Hilbert, D. M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science, 1999, 285(5425), 260-263.
18. Do, R. K.; Hatada, E.; Lee, H.; Tourigny, M. R.; Hilbert, D.; Chen-Kiang, S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med., 2000, 192(7), 953-964.
19. Petri, M.; Kim, M. Y.; Kalunian, K. C.; Grossman, J.; Hahn, B. H.; Sammaritano, L. R.; Lockshin, M.; Merrill, J. T.; Belmont, H. M.; Askanase, A. D.; McCune, W. J.; Hearth-Holmes, M.; Dooley, M. A.; Von Feldt, J.; Friedman, A.; Tan, M.; Davis, J.; Cronin, M.; Diamond, B.; Mackay, M.; Sigler, L.; Fillius, M.; Rupel, A.; Licciardi, F.; Buyon, J. P. OC-Selena Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med., 2005, 353(24), 2550-2558.
20. Petri, M.; Buyon, J.; Kim, M. Classification and definition of major flares in SLE clinical trials. Lupus, 1999, 8(8), 685-691.
21. Wallace, D. J.; Stohl, W.; Furie, R. A.; Lisse, J. R.; McKay, J. D.; Merrill, J. T.; Petri, M. A.; Ginzler, E. M.; Chatham, W. W.; McCune, W. J.; Fernandez, V.; Chevrier, M. R.; Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum., 2009, 61(9), 1168-1178.
22. Navarra, S. V.; Guzmán, R. M.; Gallacher, A. E.; Hall, S.; Levy, R. A.; Jimenez, R. E.; Li, E. K.; Thomas, M.; Kim, H. Y.; León, M. G.; Tanasescu, C.; Nasonov, E.; Lan, J. L.; Pineda, L.; Zhong, Z. J.; Freimuth, W.; Petri, M. A. BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, 2011, 377(9767), 721-731.
23. Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D. J.; Teqzova, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J. T.; Chatham, W. W.; Stohl, W.; Ginzler, E. M.; Hough, D. R.; Zhong, Z. J.; Freimuth, W.; van Vollenhoven, R. F. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte Stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum., 2011, 63(12), 3918-3930.
24. Manzi, S.; Sanchez-Guerrero, J.; Merrill, J. T.; Furie, R.; Gladman, D.; Navarra, S. V.; Ginzler, E. M.; D'Cruz, D. P.; Doria, A.; Cooper, S.; Zhong, Z. J.; Hough, D.; Freimuth, W.; Petri, M. A. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann. Rheum. Dis., 2012, 71(11), 1833-1838.
25. van Vollenhoven, R. F.; Petri, M. A.; Cervera, R.; Roth, D. A.; Ji, B. N.; Keloudis, C. S.; Zhong, Z. J.; Freimuth, W. F. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann. Rheum. Dis., 2012, 71(8), 1343-1349.
26. Boyce, E. G.; Fusco, B. E. Belimumab: Review of use in systemic lupus erythematosus. Clin. Ther., 2012, 34(5), 1006-1022.
27. Davidson, A. Targeting BAFF in autoimmunity. Curr. Opin. Immunol., 2010, 22(6), 732-739.
28. U. S. National Institutes of Health. Clinical Trials. A study of LY2127399 in patients with systemic lupus erythematosus. http://www. clinicaltrials. gov/ct2/show/NCT01196091 (Accessed February 16, 2014).
29. Ginzler, E. M.; Wax, S.; Rajeswaran, A.; Copt, S.; Hillson, J.; Ramos, E.; Singer, N. G. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther., 2012, 14(1), R33.
30. U. S. National Institutes of Health. Clinical Trials. Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (ADDRESS II). http://www. clinicaltrials. gov/ct2/show/NCT01972568 (Accessed February 16, 2014).
31. Tedder, T. F.; Tuscano, J.; Sato, S.; Kehrl, J. H. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Ann. Rev. Immunol., 1997, 15, 481-504.
32. Rossi, E. A.; Goldenberg, D. M.; Michel, R.; Rossi, D. L.; Wallace, D. J.; Chang, C. H. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood, 2013, 122(17), 3020-3029.
33. Dorner, T.; Kaufmann, J.; Wegener, W. A.; Teoh, N.; Goldenberg, D. M.; Burmester, G. R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematous. Arthritis Res. Ther., 2006, 8(3), R74.
34. Wallace, D. J.; Gordon, C.; Strand, V.; Hobbs, K.; Petri, M.; Kalunian, K.; Houssiau, F.; Tak, P. P.; Isenberg, D. A.; Kelley, L,; Kilgallen, B.; Barry, A. N.; Wegener, W. A.; Goldenberg, D. M. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicenter studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013, 52(7), 1313-1322.
35. Wallace, D. J.; Kalunian, K. C.; Petri, M. A.; Strand, V.; Houssiau, F. A.; Pike, M.; Kilgallen, B.; Bongardt, S.; Barry, A.; Kelley, L.; Gordon, C. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematous: results from EMBLEM, a phase IIb, randomized, double-blind, placebocontrolled, multicenter study. Ann. Rheum. Dis., 2014, 73(1), 183-190.
36. U. S. National Institutes of Health. Clinical Trials. Study of Epratuzumab Versus Placebo in Subjects with Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1). http://www. clinicaltrials. gov/ct2/show/NCT01262365 (Accessed February 17, 2014).
37. U. S. National Institutes of Health. Clinical Trials. Study of Epratuzumab Versus Placebo in Subjects with Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2). http://www. clinicaltrials. gov/ct2/show/NCT01261793 (Accessed February 17, 2014).
38. U. S. National Institutes of Health. Clinical Trials. Phase 1b Study of SC Milatuzumab in SLE. http://clinicaltrials. gov/ct2/show/NCT01845740 (Accessed February 17, 2014).
39. Frolich, D.; Blassfeld, D.; Reiter, K.; Giesecke, C.; Daridon, C.; Mei, H. E.; Burmester, G. R.; Goldenberg, D. M.; Salama, A.; Dorner, T. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther., 2012, 14(2), R54.
40. U. S. National Institutes of Health. Clinical Trials. Omalizumab for Lupus. http://clinicaltrials. gov/ct2/show/NCT01716312 (Accessed February 17, 2014).
41. Petri, M.; Wallace, D. J.; Spindler, A.; Chindalore, V.; Kalunian, K.; Mysler, E.; Neuwelt, C. M.; Robbie, G.; White, W. I.; Higgs, B. W.; Yao, Y.; Wang, L.; Ethgen, D.; Greth, W. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: A phase 1 randomized, controlled, dose-escalation study. Arthritis Rheum., 2013, 65(4), 1011-1021.
42. U. S. National Institutes of Health. Clinical Trials. A study to evaluate the efficacy and safety of Sifalimumab in adults. http://clinicaltrials. gov/ct2/show/NCT01283139 (Accessed February 17, 2014).